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Corepressors play a crucial role in negative gene regulation
and are defective in several diseases. BCoR is a corepressor
for the BCL6 repressor protein. Here we describe and func-
tionally characterize BCoR-L1, a homolog of BCoR. When
tethered to a heterologous promoter, BCoR-L1 is capable of
strong repression. Like other corepressors, BCoR-L1 associ-
ates with histone deacetylase (HDAC) activity. Specifically,
BCoR-L1 coprecipitates with the Class II HDACs, HDAC4,
HDAC5, and HDAC7, suggesting that they are involved in its
role as a transcriptional repressor. BCoR-L1 also interacts
with the CtBP corepressor through a CtBP-interacting motif
in its amino terminus. Abrogation of the CtBP binding site
within BCoR-L1 partially relieves BCoR-L1-mediated tran-
scriptional repression. Furthermore, BCoR-L1 is located on
the E-cadherin promoter, a known CtBP-regulated promoter,
and represses the E-cadherin promoter activity in a reporter
assay. The inhibition of BCoR-L1 expression by RNA-medi-
ated interference results in derepression of E-cadherin in
cells that do not normally express E-cadherin, indicating that
BCoR-L1 contributes to the repression of an authentic
endogenous CtBP target.
The overall transcriptional output of a cell depends on the
coordinated silencing or activation of gene expression by the
action of DNA-bound transcriptional repressors or activa-
tors (1). Coregulator proteins, including coactivators and
corepressors, interact with DNA-bound transcription fac-
tors to mediate gene activation or repression, respectively,
by recruiting multiprotein catalytic complexes that regulate
chromatin structure and thus the transcription of target
genes.
Although the role of coactivator proteins in transcriptional
regulation is well established, the equally important role of
corepressor proteins in gene regulation has become apparent
only relatively recently. There are many corepressor proteins,
recruited to a wide range of transcriptional silencers. They reg-
ulate many processes, including differentiation, proliferation,
apoptosis, and the cell cycle (2). The aberrant function of core-
pressors can lead to developmental defects and disease, since
genes that should be turned off are instead aberrantly
expressed, or “derepressed” (3). Alternately, overactive repres-
sion leads to enhanced silencing and has been reported in sev-
eral types of leukemia, involving gene fusions to transcriptional
silencers (4). Increased corepressor binding to these fusion pro-
teins leads to inappropriate repression of target genes impor-
tant for normal cellular differentiation.
Corepressors act within multiprotein complexes contain-
ing DNA-binding proteins, histone deacetylases, methyl-
CpG-binding proteins, nucleosomal histones, and the basal
transcriptional machinery. The same corepressor can be
found in different corepression complexes, and multiple
corepressors can be used by individual silencers. Corepres-
sors are thought to bridge the interaction between DNA-
bound transcriptional repressors and the chromatin-modi-
fying enzymes that mediate repression. They typically act in
multiple ways, including via the targeted modification of
chromatin structure, nucleosomal remodeling, and seques-
tration of the basal transcription machinery as well as by
inhibiting trans-activation (2).
Lysine acetylation of the histone tails is a major modification
associated with transcriptional activation, and in contrast,
deacetylation is associated with transcriptional repression. It is
thought that the acetylation of the lysine residues of the core
histone tails neutralizes the positive charge on the lysine resi-
due, thereby resulting in a more open structure of chromatin
because of the decreased affinity between the histone and the
DNA (5, 6). Chromatin is therefore more accessible to tran-
scription factors and other proteins. Conversely, the deacetyla-
tion of histone substrates results in chromatin condensation
and inhibits the accessibility of transcription factors and other
proteins to the DNA.
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The acetylation reaction is a reversible process, catalyzed by
the opposing activity of histone acetyltransferases and deacety-
lases (HDACs)3 in vivo. There are several classes of histone
acetyltransferases, each employing different mechanisms of
catalysis (7). Likewise, there are three main classes of HDACs
grouped according to homology to their counterparts in yeast,
their subcellular localization, and enzymatic activities (8, 9).
Class I (HDAC1, -2, -3, and -8; homologous to yeast Rpd3) are
ubiquitously expressed and are primarily localized in the
nucleus. Class II (HDAC4, -5, -6, -7, -9, and -10; homologous to
Hda1) are expressed in a tissue-specific manner and shuttle
between the nucleus and cytoplasm (10). Class III (Sirt1, -2, -3,
-4, -5, -6, and -7; similar to Sir2) use a different mode of catal-
ysis, relying on NAD (11). Most targets are histones, although
other proteins are deacetylated as well, including -tubulin
(12). All known repression complexes employHDACs tomedi-
ate their repression.
CtBP is also a critical component of many transcriptional
repression complexes (reviewed inRef. (13).Microarray studies
from CtBP knock-out mice implicate CtBP in the repression of
genes involved in apoptosis and in the epithelial-to-mesenchy-
mal transition (18, 19). To mediate its repression, it recruits
enzymes involved in transcription repression, such as methy-
lases and deacetylases, to the sequence-specific DNA-binding
proteins via a conserved PXDLS CtBP interaction motif in the
CtBP-interacting proteins (14, 15). Recently, it has been shown
that many histone acetyltransferases contain the PXDLS motif
and that CtBP inhibits histone acetylation by blocking access of
nuclear histone acetyltransferases to their target (16, 17).
Interestingly, CtBP structure is similar to a subfamily of
NAD-dependent dehydrogenases, and biochemical and
structural studies have recently demonstrated that CtBP pos-
sesses dehydrogenase activity (20–22). CtBP bindsNADHwith
a higher affinity than NAD (22), although this has been con-
troversial (20). CtBP function is regulated by the relative levels
of NAD and NADH within the nucleus, suggesting a role for
CtBP in sensing the redox state of the cell and regulating tran-
scription accordingly (22, 23). Current models suggest that
increases inNADH levels promoteCtBPdimerization,which in
turn increases the interaction between CtBP and proteins con-
taining the PXDLS CtBP-recruitment motif.
We have identified a novel PXDLS-containing protein desig-
nated as BCoR-L1 in the GenBankTM data base. BCoR-L1 is
related to the BCoR, a transcriptional corepressor that potenti-
ates BCL6 repression in reporter assays (24). BCL6 is a tran-
scription factor that is required for germinal center formation
and is linked to lymphomagenesis (25).We find that, like BCoR,
BCoR-L1 functions as a corepressor when tethered to DNA.
BCoR-L1 interacts withClass IIHDACs,HDAC4,HDAC5, and
HDAC7, suggesting that they are involved in its function as
transcriptional corepressor. It mediates its repression through
recruitment of the CtBP corepressor protein and affects the
repression of at least one CtBP target, the tumor suppressor
protein, E-cadherin.
MATERIALS ANDMETHODS
Cloning of Full-length BCoR-L1 and Other Plasmids—Full-
length BCoR-L1 (BCoR-L1a) andExon9 BCoR-L1 (BCoR-L1)
cDNAs were produced in two stages. The C terminus of
BCoR-L1 was PCR-cloned using Pfu polymerase from cDNA
derived from the normal ovarian epithelial cell line (HOSE
17.1). Primers used for this PCRwere designed from the in silico
predictions of the mRNA and later from known sequence. The
cDNA was amplified in several overlapping fragments, which
were cloned into the pPCR-Script vector (Stratagene) and later
assembled into a single sequence using appropriate restriction
enzyme sites. The N terminus of BCoR-L1 was provided by a
partial cDNA clone (bp 60–4449, FLJ00190), which was a gen-
erous gift of Kasuza Institute (Chiba, Japan). The first 60 bp of
BCoR-L1 were incorporated into primers, which were used to
amplify the N terminus of BCoR-L1 from the cDNA clone and
then subcloned into the existing C terminus of BCoR-L1. The
entire coding sequences for BCoR-L1 were then subcloned into
pEGFP-C1 (Clontech) and pFLAG-CMV-2 (Sigma) parent
plasmids using SalI and BamHI sites.
GST-BCoR-L1a-(1328–1785) vector for antibody produc-
tion was constructed by cloning BCoR-L1 sequence (amino
acids 1328–1785) in framewith pGEX-5X-1. The pSUPER vec-
tor system (26) (a gift ofDr. ReuvenAgami;NetherlandsCancer
Institute, Amsterdam) was used to create the siRNA construct
to knock-down BCoR-L1 levels “pSUPER-BcoR-L1.” The fol-
lowing sequencewas cloned into the pSUPERvector to produce
pSUPER-BCoR-L1: forward (FWD), 5-GATCCCCCGTGGC-
AGAGGCTGAGGGCTTCAAGAGAGCCCTCAGCCTCTG-
CCACGTTTTTGGAAA-3; reverse (RVS), 5-AGCTTTTC-
CAAAAACGTGGCAGAGGCTGAGGGCTCTCTTGAA-
GCCCTCAGCCTCTGCCACGGGG-3. This construct
generated siRNAs targeting the following 21-nucleotide
sequence: 5-CGTGGCAGAGGCTGAGGGCT-3 (comple-
mentary to nucleotides 312–331 within BCoR-L1 cDNA). The
pSUPER-GFP plasmid has been described previously (27). Gal4
DNA-binding domain (Gal4-DBD) vectors were constructed
by replacing GFP from pEGFP vectors (Clontech) with the
Gal4-DBD from pGBT9 (Clontech). BCoR-L1 was cloned as a
Gal4-DBD fusion protein using SalI and BamHI sites. BCoR-L1
fragments were cloned as Gal4-DBD fusion proteins using
BamHI and EcoRI sites incorporated into primers designed to
amplify the fragments from plasmid. The Gal4-DBD-BCoR-L1
CtBP binding site mutant (PLDLS to PLASS) was created
using the QuikChangeTM site-directed mutagenesis method
(Stratagene). FLAG-tagged expression vectors forHDAC4 to -7
(28, 29), the pGL3-hE-cad (E-Cad-Luc) (15), and Myc-tagged
CtBP1 expression vectors (30) have been described previously
(31, 32). The GFP-BCoR plasmid was subcloned from Myc-
BCoR (kindly provided by Vivian Bardwell, University of Min-
nesota, Minneapolis, MN).
Northern Analysis—The probe for Northern analysis was
prepared from RT-PCR products derived from the amino
terminus of BCoR-L1 amplified from the HOSE 17.1 ovarian
cell line using the following primer sequences: forward, 5-
3 The abbreviations used are: HDAC, histone deacetylase; siRNA, small inter-
fering RNA;DBD,DNA-bindingdomain; GFP, green fluorescent protein; RT,
reverse transcription; Luc, luciferase; TK, thymidine kinase; E-Cad, E-cad-
herin; WT, wild type; BCoR, BCL6 corepressor; BCoR-L1, BCoR-like 1.
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GTGCACAACTGGACCAGTTCTGACCG-3; reverse, 5-
GAGTCAGAGATGAGCGTGGGCACTG-3. Probes were
[-32P]dCTP-labeled using the MegaPrime kit (Amersham
Biosciences). Hybridization to a Clontech humanMultiple Tis-
sue Northern blot II membrane was carried out for 2 h in
ExpressHyb solution (Clontech) at 65 °C, followed by a stand-
ard washing procedure.
Cell Culture and Transfections—Cells were maintained at
37 °C in a 5% CO2 incubator and grown in RPMI 1640 medium
supplemented with 10% Serum Supreme, 1% L-glutamine, 100
units/ml penicillin, and 100 units/ml streptomycin. Transfec-
tions of cells were carried out using either electroporation or
lipofection. For electroporation, 293T cells in exponential
growth were pelleted and resuspended at 106 cells/300 l in
complete media and then electroporated at room temperature
with 7 g of DNA in a 0.4-cm cuvette (Interpath). Electropora-
tion was performed with a BTXTM820 electroporator (Gen-
etronics Inc.) at 260 Vwith a time constant of 10ms. HeLa cells
growing in dishes were transfected using LipofectamineTM
2000 reagent (Invitrogen) according to the manufacturer’s
instructions.
Luciferase Assays—293T cells were grown in 24-well dishes
and were transfected using LipofectamineTM 2000. The
pRL-TK plasmid (Promega) was cotransfected as a control for
transfection efficiency. The amount of DNA per well was kept
constant using an empty expression vector (pCMV; Strat-
agene). Cellswere grown for 48hprior to harvesting usingPassive
Lysis Buffer (Promega, Annandale, Australia). The lysate was
assayed for luciferase activity using the Dual-LuciferaseTM
reporter assay system (Promega), according to themanufacturer’s
recommendations. Readings were taken using a TD-20/20 Lumi-
nometer (TurnerDesigns). Results shown are from representative
experiments. The error bars represent one S.D.
Antibodies and BCoR-L1 Antibody Production—Polyclonal
antibodies were produced in rabbits following standard injec-
tion protocols. Rabbits were immunized with GST-BCoR-L1a-
(1328–1785) fusion protein. An -BCoR-L1 peptide antibody
was raised against the sequence EERRAPLSDEESTTGD by
Open Biosystems. The following antibodies were used: rabbit
anti-GFP (Molecular Probes), mouse monoclonal anti-FLAG
(Sigma), mouse monoclonal anti-Myc (Cell Signaling Technol-
ogy), ImmunoPure Recomb Protein A/G HRP conjugate
(Molecular Probes), and rabbit anti-Gal4-DBD (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA).
ChIP Analysis and RT-PCR—ChIP analysis of the E-cadherin
promoter was performed according to Shi et al. (15). The PCR
primers used to amplify the E-cadherin promoter were as follows:
forward, 5-TAGCCTGGCGTGGTGGTGTGCACCTG-3;
reverse, 5-GTGCGTGGCTGCAGCCAGGTGAGCC-3. The
following primers were used for quantitative PCR detection
of BCoR-L1 levels: forward, 5-GACCGACATCCTGAACA-
TCC-3; reverse, 5-ATAGGACAGCAGGAGCCAGA-3.
The primers used to detect E-cadherin levels were as follows:
forward, 5-GAAAATCTGAAAGCGGCTGAT-3; reverse,
5-GCCCCATTCGTTCAAGT-3.
Lysate Preparation, Coimmunoprecipitation, Immunoblot-
ting, and Antibodies—Cell extracts were prepared by lysis in
universal immunoprecipitation buffer (50 mM Tris-HCl (pH
7.4), 150 mM NaCl, 2 mM EDTA, 25 mM -glycerophosphate,
0.2% Triton X-100, and 0.3% Nonidet P-40), supplemented
with 25mM sodium fluoride, 25 mM sodium orthovanadate, 0.1
mM phenylmethylsulfonyl fluoride, and a mixture of protease
inhibitors (Roche Applied Science). For coimmunoprecipita-
tion experiments, protein samples were precleared by incuba-
tionwith proteinG-Sepharose beads (Sigma) for 30min at 4 °C.
Supernatants (2mg)were incubatedwith 2g of antibody over-
night. Immune complexes were collected with protein
G-Sepharose beads. Beads were washed four times with lysis
buffer, eluted using Laemmli sample buffer, and analyzed by
immunoblotting with specific antibodies.
Immunofluorescence Staining—Cells grown on coverslips
were fixed in 4% paraformadehyde in phosphate-buffered
saline and permeabilized in 0.2% Triton X-100 in phosphate-
buffered saline. Coverslips were blocked with 0.5% bovine
serum albumin in phosphate-buffered saline and then incu-
bated with primary antibodies diluted in blocking solution for
1 h at room temperature, followed by AlexaFluor-546-conju-
gated secondary antibodies (Molecular Probes). Cells were
counterstained with 4,6-diamidino-2-phenylindole (Molecu-
lar Probes). Coverslips were mounted on glass slides with
Mowiol (Calbiochem) containing 0.6% diazobicyclo-octane
(Sigma). Fluorescence was visualized using a Zeiss Axioskop
20microscope, Zeiss AxioCamMRc digital camera, andMRGrab
1.0 software. Dual confocal images were collected sequentially
using a 635 objective on Leica TCS SP2 confocal fluorescent
microscope system using a 488-nm argon laser for GFP and
543-nmhelium-neon laser to excite theAlexaFluor-546.Confocal
hardware was driven by a work station running Leica confocal
imaging software. FigureswereprocessedusingAdobePhotoshop
6.0.
FIGURE 1. Schematic representation of BcoR-L1. BCoR-L1 exists as at least
two isoforms. An additional exon, designated exon 9 (Ex9), is present in
BCoR-L1a. The recognizable domains andmotifs are indicated. BCoR-L1 con-
tains a nuclear localization signal (NLS) and tandem ankyrin repeats (ANK). It
also contains two LXXLL motifs known to recruit nuclear receptor coregula-
tors. The proteins that share sequence similarity with BCoR-L1 are repre-
sented under BCoR-L1. The numbers represent percentage identity/percent-
age homology between BcoR-L1 amino acid sequence and its homologs. The
region of homology between BCoR-L1 and BARD1 spans 431 amino acids.
The region of homology with RRP1 spans 351 amino acids. There are three
regions of homology between BCoR and BCoR-L1: one small amino-terminal
region and two substantial regions spanning 600 amino acids and 336 amino
acids within the central region and carboxyl terminus, respectively.
ANovel CtBP-interacting Corepressor
15250 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 20•MAY 18, 2007
 at Queensland Univ of Technology (CAUL) on M
ay 14, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
RESULTS
A Novel BCoR-related Protein—BCoR-L1 (BCoR-like 1) was
isolated as a partial cDNA using full-length BRCA1 as bait in a
yeast two-hybrid screen with a testis cDNA library. The basis
and significance of the interaction with BRCA1 is currently
under investigation and is not discussed here. One set of posi-
tive clones encoded the partial cDNA of a hypothetical protein
(GenBankTM number NM_019294, BCL6 corepressor-like 1;
function unknown), expressed from the X chromosome
(Xq25–26.1). The entire BCoR-L1 transcript contains 14 exons
spliced from75 kb of genomic DNA. The original yeast two-
hybrid clone contained an additional exon (exon 9) not present
in the composite sequence on GenBankTM and represents an
alternatively spliced form of BCoR-L1 mRNA, which we call
BCoR-L1a. The complete cDNA sequence of full-length
BCoR-L1 (BCoR-L1a) and BCoR-L1 Exon 9 (BCoR-L1;
NM_019294) was generated in mammalian expression vectors
(see “Materials and Methods”).
The open reading frame of BCoR-L1 cDNA encodes a pro-
tein of 1711 amino acids containing a putative bipartite nuclear
localization signal (NLS) and tandem ankyrin repeats (ANK)
(Fig. 1). BCoR-L1a is 1785 amino acids long. Neither BCoR-L1
nor BCoR has identifiable DNA-binding domains. BCoR-L1
contains a PXDLS motif, involved in binding the CtBP core-
pressor (33, 34). BCoR-L1 also contains two LXXLL nuclear
receptor recruitmentmotifs found in coregulator proteins (35).
The amino acid sequence shares homology with several pro-
teins involved in chromatin remodeling, transcription, and
repair of DNA damage. More specifically, BCoR-L1 is homolo-
gous to BCoR, a transcriptional corepressor for the BCL6 tran-
scriptional repressor (24). Additionally, part of the BCoR-L1
sequence shares homology with the predominant BRCA1-in-
teracting protein, BARD1 (36). A region of BCoR-L1 is related
to the Drosophila recombination repair protein (dRRP1), a
repair endonuclease. Although BCoR-L1 lacks the RRP1 nucle-
ase domain, it shares homology with the RRP1 domain that
catalyzes strand transfer during homologous recombination
(37, 38). A high degree of sequence conservation exists between
human BCoR-L1 and mouse and rat orthologues (80 and 77%
amino acid identity, respectively). We have not been able to
identify any BCoR-L1 orthologues in lower eukaryotes.
Tissue Expression of BCoR-L1—Northern blot analysis using
the multiple-tissue Northern II filter (Clontech) demonstrated
that BCoR-L1 is expressed at low levels in many tissues. The
FIGURE 2. Tissue expression of BCoR-L1. A, Northern blot analysis of
BCoR-L1 expression using a Clontech membrane. B, HeLa cells were trans-
fected with FLAG-tagged BCoR-L1a or BCoR-L1. Lysates from the transfected
and untransfected cells were separated on SDS-polyacrylamide gels and sub-
jected to immunoblotting using -BCoR-L1 antibody (top panel) and anti-
FLAG antibody (bottom panel). C, 293T cells were transfected with pSUPER-
GFP or pSUPER-BCoR-L1 and left for 72 h before harvesting. Lysates were
separated by SDS-PAGE and subjected to immunoblotting using the peptide
-BCoR-L1 antibody.
FIGURE 3. Localization of BCoR-L1 and BCoR. HeLa cells were transfected
with GFP-BCoR-L1 or GFP-BCoR. Cells were fixed in paraformaldehyde 24 h
later and stained with 4,6-diamidino-2-phenylindole (DAPI) to mark the cell
nucleus.
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highest level of expression was observed in testis and prostate.
Medium levels of expression were also seen in peripheral blood
lymphocytes and spleen (Fig. 2A).
A rabbit polyclonal antibody was raised against recombinant
GST-BCoR-L1a (aa 1328–1785). The specificity of the anti-
body for immunoblot analysis was tested against recombinant
FLAG-tagged BCoR-L1a and BCoR-L1 in protein extracts pre-
pared fromHeLa cells. The antibody recognized a bandmigrat-
ing through SDS-polyacrylamide
gels at a size of200 kDa and comi-
grating with exogenously expressed
FLAG-tagged BCoR-L1 (Fig. 2B).
This result provides evidence that
endogenous BCoR-L1 is predomi-
nantly encoded from the BCoR-L1
Exon 9 isoform, which was also
the predominant isoform detected
by RT-PCR analysis (results not
shown). Furthermore, this bandwas
significantly diminished in inten-
sity when cells were depleted of
BCoR-L1 by siRNA, further demon-
strating the specificity of BCoR-L1
antibody (Fig. 2C).
BCoR-L1 Is a Nuclear Protein—
Since the amino acid sequence of
BCoR-L1 contains a classical bipar-
tite nuclear localization signal and
its homolog BCoR is a nuclear pro-
tein, we expected BCoR-L1 to be
nuclear. To confirm this, BCoR-L1
was cloned as a GFP fusion protein
and transfected into HeLa cells, and
its localization was examined by
epifluorescence microscopy. GFP-
BCoR-L1 localized exclusively in
the nucleus and was distributed in a
heterogeneous subnuclear pattern
of dots (Fig. 3). Between 5 and 30
bright dots were scattered through-
out the nucleus of each cell. Inter-
estingly, its pattern of localization
differed from that of GFP-BCoR.
Although a substantial proportion
of GFP-BCoR-L1 was present in the
nucleosol, BCoR was exclusively
found in many speckle-like dots of a
consistent size. On the other hand,
GFP-BCoR-L1 localization was
highly heterogeneous, with cells dis-
playing dots of various dimensions
and number, suggesting that
BCoR-L1 localization could be reg-
ulated through the cell cycle.
BCoR-L1 Is a Strong Transcrip-
tional Repressor—We next exam-
ined whether BCoR-L1 is able to
regulate transcription, given its high
homology to the BCoR corepressor. We used a standard lucif-
erase reporter system in transient transfection assays. We
cloned BCoR-L1 as aGal4-DBD fusion protein, which recognizes
theGal4 binding sites upstreamof a luciferase reporter gene (Luc)
driven by the herpes simplex virus (HSV) thymidine kinase (TK)
promoter (TK-Luc). The activity exhibited in cells transfected by
theLucreporterwithGal4-DBDvectoralonewasconsidered tobe
the basal transcriptional activity. When expressed in fusion with
FIGURE 4.BCoR-L1 can repress basal and activated transcription.A, the TK-Luc reporter construct was cotrans-
fected into 293T cells along with the indicated amounts of the Gal4-DBD-BCoR-L1 or FLAG-BCoR-L1 expression
constructs.B, LexA-Gal4-Luc reporter andVP16-LexAexpressionconstructswere transfected intocellswith increas-
ingdosesofGal4-DBD-BCoR-L1.C,BCoR-L1wasdividedintofiveoverlappingfragmentsandexpressedasGal4-DBD
fusion proteins. Cells were cotransfected with TK-Luc reporter construct and 40 ng of each Gal4-DBD fusion frag-
ment of BCoR-L1 or full-length GAL-DBD-BCoR-L1. The CtBP binding motif in Fragment 2 (amino acids (aa) 360–
675) (Frag2CtBP) of BCoR-L1wasmutated fromPLDLS toPLASS, and its effecton luciferaseactivitywas compared
withWTFragment2. TheemptyGal4-DBDconstructwas transfected intocells as a control, and itsbasal activitywas
arbitrarily defined as 1. Luciferase assayswereperformedon cell extracts 24h after transfection. Data represent the
averageof samples in triplicatewithS.D.values shownaserrorbars. Relative luciferaseactivity (RLA)wasdetermined
by normalizing luciferase values to cotransfected Renilla luciferase activity.WB, Western blot.
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the Gal4-DNA binding domain (Gal4-DBD), BCoR-L1 repressed
expression of the Luc reporter gene in a dose-dependentmanner.
Comparable expression of FLAG-tagged BCoR-L1, which is not
tethered to the Gal4 sites, did not repress luciferase activity, dem-
onstrating that BCoR-L1 is able to repress basal transcription only
when physically tethered to a heterologous promoter (Fig. 4A).
To determine whether BCoR-L1 was able to repress acti-
vated transcription, Gal4-DBD-BCoR-L1 was cotransfected
with VP16-LexA, a strong transcriptional activator. In this
assay, the LexA-VP16 transcriptional activator drives a LexA-
responsive promoter, and the reporter construct encodes the
luciferase gene with the Gal4-binding sites upstream of two
LexA binding sites (39). LexA-VP16 activated the LexA-lucif-
erase reporter gene300 fold. Gal4-DBD-BCoR-L1was able to
reduce VP16-mediated transactivation significantly, in a dose-
dependent manner (Fig. 4B), thereby demonstrating that
BCoR-L1 can repress activated transcription.
To identify the regions in BCoR-L1 that mediate repression,
we dividedBCoR-L1 cDNA into five overlapping fragments and
expressed them as Gal4-DBD fusion proteins. Each fragment
expressed a protein of the expected size.When these fragments
were tested for repression in the luciferase assay, Fragment 2
(amino acids 360–675) of BCoR-L1 was sufficient for maxi-
mum repression, indicating that the repressive activity of
BCoR-L1 is mediated through this domain. The amino acid
sequence of Fragment 2 (amino acids 360–675) of BCoR-L1
contains a classical CtBP1/2 binding motif, PXDLS. Therefore,
to test the hypothesis that CtBP is involved in repression
through this domain, the CtBP recruitment motif was mutated
from PLDLS to PLASS, and its effect on repressor function was
comparedwith that ofwild-type Fragment 2. Themutated frag-
ment was no longer capable of efficient repression (Fig. 4C).
CtBP Is Required for BCoR-L1 Repression—We next studied
the interaction of the full-length BCoR-L1 with CtBP1 using
coimmunoprecipitation experiments. Myc-CtBP1 specifi-
cally coprecipitated with GFP-BCoR-L1. Similarly, GFP-
BCoR-L1 coprecipitated withMyc-CtBP1 (Fig. 5A). After the
consensus CtBP-binding site in BCoR-L1 was mutated from
PLDLS (WT-BCoR-L1) to PLASS (CtBP-BCoR-L1), CtBP-
BCoR-L1 was no longer capable of interacting with CtBP in
reciprocal coimmunoprecipitation experiments, demonstrat-
ing that BCoR-L1 recruits CtBP via a classical CtBP-binding
motif. In addition, mutation of the CtBP consensus binding
motif in full-length Gal4-DBD-BCoR-L1 (from PLDLS to
PLASS) significantly impaired repression at the Gal4-respon-
sive promoter in a dose-dependent manner (Fig. 5B). Our
results indicate that recruitment of CtBP is one mechanism
employed by BCoR-L1 to achieve its repression.
BCoR-L1 Associates with Class II HDACs—The mechanism
most commonly employed by repressors involves the recruit-
ment of HDACs that remove acetyl groups from the terminal
tails of histones. To investigate whether BCoR-L1 is associated
with specific HDACs, we coexpressed GFP-BCoR-L1 and the
FLAG-tagged mammalian expression constructs encoding the
human Class I and Class II HDACs (HDAC1 to -7). Apart from
HDAC6, which was exclusively cytoplasmic, as has been previ-
ously reported (40), each HDAC was observed in the nucleus,
with various levels also present in the cytoplasm. GFP-
BCoR-L1 colocalized with the class II HDACs, HDAC4,
HDAC5, andHDAC7,within dots of various dimensionswithin
the nucleus (Fig. 6A). Interestingly, we saw a striking redistri-
bution of BCoR-L1 into large subnuclear “patches” with the
coexpression of FLAG-HDAC5. We did not observe the colo-
calization of GFP-BCoR-L1 with any class I HDACs (HDAC1,
-2, and -3) (HDAC2 shown) or with cytoplasmic HDAC6.
Coimmunoprecipitation experiments using FLAG-tagged
HDAC constructs confirmed the interactions between
BCoR-L1 and the individual HDACs, HDAC4, -5, and -7 (Fig.
6B). BCoR-L1 did not coprecipitate with Class I HDACs (not
shown). Furthermore, the interaction between Class II HDACs
and BCoR-L1 was not facilitated through CtBP, because
CtBP-BCoR-L1 interacted equivalently with these HDACs.
Overall, the colocalization and coprecipitation of BCoR-L1
with Class II HDACs suggests that BCoR-L1 function relies on
class II HDAC activity.
BCoR-L1 Resides on the E-cadherin Promoter—E-cadherin
is a well characterized target of CtBP in vivo. CtBP associates
FIGURE 5. Transcriptional repression by BCoR-L1 is partially mediated
through CtBP. A, mutation of the CtBP binding site in BCoR-L1 abolishes the
interaction between CtBP and BCoR-L1. WT-GFP-BCoR-L1 or CtBP-GFP-
BCoR-L1was cotransfectedwithMyc-CtBP1 into 293T cells. Reciprocal immu-
noprecipitations using Myc or GFP antibodies were performed, followed by
Western blotting as shown. B, mutation of the CtBP binding site within
BCoR-L1 attenuates repression by BCoR-L1. 293T cells were cotransfected
with the Gal4-TK-Luc reporter and either WT-Gal4-DBD-BCoR-L1 or CtBP-
Gal4-DBD-BCoR-L1, and the relative luciferase activity (RLA) was assayed.
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with the E-cadherin promoter to
promote its repression, and
accordingly, down-regulation of
CtBP results in derepression of
E-cadherin transcription in cells
that do not normally express
E-cadherin (15, 18, 22, 41). We
performed chromatin immuno-
precipitation assays to evaluate
whether BCoR-L1 associates with
the same region of the E-cadherin
promoter as CtBP. As previously
shown, Myc-CtBP physically asso-
ciated with the endogenous E-cad-
herin promoter. GFP-BCoR-L1 also
associated with the E-cadherin pro-
moter, indicating that BCoR-L1 and
CtBP share E-cadherin as a com-
mon target (Fig. 7A). Next, we used
an E-cadherin promoter luciferase
reporter gene (E-Cad-Luc) (427 to
53; containing the full-length
E-Box) to determine if BCoR-L1
was able to repress transcription
from the E-cadherin promoter.
293T cells were cotransfected with E-Cad-Luc and either WT-
BCoR-L1 orCtBP-BCoR-L1, and luciferase activity wasmeas-
ured. WT-BCoR-L1 was able to significantly suppress lucifer-
ase activity driven by the E-Cad promoter. CtBP-BCoR-L1
was not able to reduce E-Cad promoter activity to the same
extent as WT-BCoR-L1, suggesting that CtBP is partially
required for BCoR-L1-mediated repression of E-cadherin (Fig.
7B). Next, we used siRNA to reduce BCoR-L1 levels and tested
whether the reduction of BCoR-L1 decreases the repression of
E-cadherin transcription in E-Cad-negative U2OS cells. We
used the pSUPER vector system (26) to direct the synthesis of
siRNAs to specifically knock down BcoR-L1 levels. We meas-
ured E-cadherin transcript levels by RT-PCR in U2OS cells
transfected with pSUPER-BCoR-L1 (depleted of BCoR-L1) or
pSUPER-GFP (as control). In these experiments, BCoR-L1 lev-
els were reduced to20%, as determined by RT-PCR (data not
shown). A reduction of expression of BCoR-L1 resulted in an
2.5-fold increase in the transcript levels of E-cadherin (Fig.
7C). Taken together, these data indicate that BCoR-L1 is
directly involved in the repression of E-cadherin, an authentic
CtBP target gene.
DISCUSSION
BCoR-L1 fits the definition of a corepressor protein in that,
although it lacks a DNA-binding domain, it has a portable
repression domain and is capable of repression when recruited
to promoters. It exhibits a number of similarities with BCoR.
They are both large proteins and in fact only differ in size by 10
amino acids (BCoR is 1721 amino acids) containing ankyrin
repeats of unknown function, although presumably they are
protein-protein interaction modules (42). BCoR was identified
as a corepressor of the BCL6 transcriptional repressor (24).
Unlike BCoR, BCoR-L1 does not interact with BCL6 or poten-
FIGURE 6. BCoR-L1 interacts with Class II HDACs. A, HeLa cells were cotransfected with GFP-BCoR-L1 (green)
and each of themammalian FLAG-taggedHDAC constructs. Cells were stainedwith the-FLAG antibody (red)
and viewed using confocal microscopy. B, 293T cells were cotransfected with individual FLAG-tagged Class II
HDACs and either Gal4-WT-BCoR-L1 or Gal4-CtBP-BCoR-L1. Extracts were immunoprecipitated (IP) with the
anti-FLAG antibody and immunoblotted (IB) using anti-Gal4-DBD antibody. Input is one-twentieth of the total
immunoprecipitate.
FIGURE 7. BCoR-L1 contributes to the repression of E-cadherin. A, ChIP
analysis of the E-cadherin promoter. Myc-CtBP1 or GFP-BCoR-L1 was precip-
itated from U20S cells, and coprecipitating chromatin was subjected to PCR
to amplify the E-cadherin promoter. B, 293T cells were cotransfected with
E-Cad-Luciferase and either Gal4-WT-BCoR-L1 or Gal4-CtBP-BCoR-L1. Lucif-
erase activity was monitored 24 h later. C, U2OS cells were transfected with
pSUPER-BCoR-L1 (to deplete BCoR-L1 levels) or pSUPER-GFP (as control). RNA
was taken 72h later, and the levels of E-cadherin transcriptweremeasuredby
quantitative PCR. Results shown are the average of three separate experi-
ments repeated in duplicate.
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tiate BCL6-mediated repression (data not shown), providing
evidence that BCoR-L1 and BCoR may have distinct functions
in human cells. However, BCoR is likely to have roles independ-
ent of BCL6, given its ubiquitous expression in tissues where
BCL6 is not expressed. Furthermore, we found that BCoR-L1 is
expressed atmuch higher levels in the hormone-responsive tis-
sues, prostate and testis, than in other tissues.
Typically, corepressors recruitmultiple cofactors involved in
chromatin remodeling, histone deacetylation, or basal tran-
scription to mediate concerted transcriptional silencing
through multiple repression pathways. We have shown that
BCoR-L1 achieves its repression in at least two ways, via an
interaction with the CtBP corepressor and possibly via Class II
HDACs. Elimination of the CtBP-binding site within BCoR-L1
partially relieves BCoR-L1-mediated transcriptional repres-
sion, demonstrating that BCoR-L1 repression is mediated
through CtBP. Since CtBP has been shown to be regulated by
fluctuating levels of NADH in the cell, this raises the possibility
that BCoR-L1 is regulated similarly (20, 22, 23).
Recently, the BCoR complexwas shown to contain Polycomb
group (PcG) proteins (NSPC1, RING1, RNF2, and RYBP) and a
JmjC domain histone H3 K36 demethylase, which is able to
removemethyl groups from lysine (43). Another complex asso-
ciated with CtBP is the LSD1-CoREST complex, capable of
demethylatingH3-K4within nucleosomes (15, 44, 45). It will be
interesting to addresswhether BCoR-L1 interacts with histone-
demethylating enzymes or Polycomb group proteins in the
same fashion as BCoR and CtBP.
Here, we have shown that BCoR-L1 is involved in the repres-
sion of E-cadherin, a known CtBP target. This repression par-
tially requires CtBP. A number of transcriptional repressors are
known to regulate E-cadherin expression, including Snail (46),
Slug (47, 48), Twist (49), and ZEB/EF1 (50, 51), and it is pos-
sible that BCoR-L1 might function together with these repres-
sors, or as part of a separate as yet unknown complex. Further-
more, it might be of great value to determine if BCoR-L1
represses the expression of other CtBP-regulated genes and
possibly those involved in promoting apoptosis (18, 19).
E-cadherin is critical to maintain normal epithelial cell con-
tact (52), and down-regulation of E-cadherin is seen in a large
percentage of carcinomas or borderline tumors (53, 54). Since
BCoR-L1/CtBP represses E-cadherin, interfering with BCoR-
L1/CtBP functionmight prevent loss of the epithelial state. This
would be the reverse of the phenotype induced by pinin/DRS,
which binds CtBP and relieves its repression of the E-cadherin
promoter (55, 56). Interestingly, CtBP binding to the E-cad-
herin promoter is induced by elevations in free NADH. This
redox-regulated repression of E-cadherin has been postulated
to be involved in increasing tumor cell migration (41). It is con-
ceivable, therefore, that interfering with CtBP and/or BCoR-L1
might inhibit tumor metastasis.
CtBP recruits Class II HDACs via consensus CtBP-binding
motifs within their amino termini (30). However, CtBP is not
required for the interaction between BCoR-L1 and Class II
HDACs, since our CtBP-BCoR-L1 was able to interact with
the Class II HDACs. It is possible that the class II HDACs inter-
act with the ankyrin repeats of BCoR-L1 directly, since they
interact with the ankyrin repeat of certain proteins, ANKRA1
(ankyrin-repeat family A protein) and ANKRA2 (57, 58).
BCoR-L1 is able to partially repress transcription independ-
ently of CtBP, suggesting a contribution from HDACs or some
other mechanism. This observation also fits with the principle
that generally, the contributions of all of the separate compo-
nents of any repressive complex act in an additive fashion to
achieve full repression.
Only a relatively small number of transcription factors are
known to interact with Class II HDACs, although interactions
have been reported between Class I HDACs and many tran-
scription factors. The colocalization and coprecipitation of
BCoR-L1 with Class II HDACs strongly, although indirectly,
suggest that BCoR-L1 function is linked to that of Class II
HDACs.Most research has focused on the association between
Class II HDACs and members of theMEF2 (myocyte enhancer
factor-2) family of MADS-box transcription factors via their
amino-terminal extensions, which results in transcriptional
repression (59–61). The MEF2 family regulate genes involved
in myogenesis and accordingly class II HDACs inhibit patho-
logic cardiac hypertrophy by modulating MEF2 transcription
factor activity (62, 63). Class II HDACs are highly expressed in
heart, skeletal muscle, and brain, in contrast to the Class I
HDACs, which have a more ubiquitous expression (64). At
present, we do not know the relative expression of BCoR-L1 in
heart, muscle, and brain, since these tissues were not repre-
sented on our Northern blot. In the future, it will be of interest
to elucidate if BCoR-L1 plays a role in myogenesis or generally
in Class II HDAC function.
We have not been able to identify of the nature of the sub-
nuclear foci containing BCoR-L1. Notably, BCoR-L1 and BCoR
localize in distinct compartments, suggesting that they have
divergent functions. Many proteins involved in transcriptional
regulation localize to specific compartments within the
nucleus. It is unknown whether these subnuclear foci are sites
of active gene silencing or are required to recruit repressors
away from sites of active transcription. Class II HDACs localize
to distinct nuclear bodies within the cell nucleus, although as
yet the function and biological significance of these dots is
unknown (10). Corepressors, such as SMRT and NCoR, are
concentrated in these nuclear foci, sometimes called deacety-
lase bodies, with the HDACs (65). One remarkable observation
is the redistribution of BCoR-L1 to large HDAC5 “patches” by
overexpression of HDAC5. Interestingly, expression of the
corepressor, NCoR, leads to recruitment of HDAC5 into
intranuclear bodies (65). The BCoR-L1-HDAC5 relocation
works in the opposite direction; rather than BCoR-L1 recruit-
ing HDAC5, our data demonstrate that HDAC5 is responsible
for the relocalization of BCoR-L1. Another similar example is
seen in the redistribution of the NCoR by the PIT-1 transcrip-
tion factor (67).
It is possible that BCoR-L1 is a substrate of theHDACs, since
there is evidence of nonhistone substrates, including p53 (68,
69) and -tubulin (40). Acetylation of a lysine residue adjacent
to the CtBP recruitment motif in E1A protein has been shown
to modulate its interaction with CtBP (34). Interestingly,
BCoR-L1 sequence also contains this flanking lysine residue,
raising the possibility that its interaction with CtBP is similarly
regulated by acetylation.
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The importance of active transcriptional repression is high-
lighted by the fact that aberrant gene silencing is linked to a
range of diseases, including developmental diseases and can-
cers (70, 71). Recently, mutations in BCoR have been linked
with the developmental abnormality oculofaciocardiodental
syndrome (66). This developmental syndrome has been linked
to two loci, MAA1 (Xq27) and MAA2 (Xp11, the BCoR locus).
Intriguingly, mutations in BCoR were found inMAA2 families.
Coincidentally, MAA1 maps extraordinarily close to the
BCoR-L1 locus. There is thus the possibility that aberrant
BCoR-L1 function may contribute to this disease.
Acknowledgment—We gratefully acknowledge Vivian Bardwell (Uni-
versity ofMinnesota,Minneapolis, MN) for providing theMyc-tagged
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